It was another up day for the AIM index, although it was the start of trade in the US and the response to that slightly softer than expected inflation print that drove sentiment. The junior market finished the day two and a half points higher at 819.38.
- ITSARM +52%
- System1 +27%
- Immupharma +14%
- Bezant Resources -36%
- Craven House -17%
The recently renamed Itsarm LON:ITS, formerly known as In the Style, found itself at the top of the board today, sitting some 52% higher. That’s no doubt a welcome relief for long term investors who have seen the stock tank since its IPO just over two years ago.
System1 LON:SYS1 was the day’s second best performer, up 27%. A trading update this morning covering the final quarter impressed with a solid performance in the US seemingly a stand out. Management believe they have the right combination of strategy and management in place to sustain growth into the future.
Immupharma LON:IMM gets the notable mention, adding 14% off the back of a clinical program update. That was confirming a meeting with the FDA for next month, with a meaningful uptick in volumes being seen.
Bezant Resources LON:BZT was the day’s laggard following news of a share issue to settle some outstanding debts. Shares in the company fell 36%, largely reflecting the dilution impact of the issue.
- AIM Market Roundup: Immupharma, Poolbeg, Xeros
- Three Quick Facts: Norman Broadbent, Computacenter, Immupharma
- Small Cap Stocks: Immupharm, Ondine Biomedical, Beacon Energy
Craven House LON:CRV was also deflated, off some 17% at the close. However there’s no meaningful news here with very limited trade and a huge spread being recorded on the stock.
